Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update
Garrett Lawlor, Alan C MossBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USAAbstract: Infliximab is a monoclonal antibody against tumor necrosis factor (TNF) which has become an established therapy for Crohn’s disease over the last 10 years. Given the sim...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-12-01
|
| Series: | Clinical and Experimental Gastroenterology |
| Online Access: | http://www.dovepress.com/cause-for-controversy-infliximab-in-the-treatment-of-ulcerative-coliti-a3822 |